Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the U.S. Food and Drug Administration (FDA) conducted an inspection at Aurobindo Pharma, Unit XIV, FEI 3014477031, located at Plot No 17, E-Bonangi Village, Jawaharlal Nehru Pharma City, Parawada Mandal, Anakapalli District, Andhra Pradesh, from 15th May to 19th May 2023. The Unit has now received Establishment Inspection Report classifying the facility as ‘Voluntary action indicated’ (‘VAI’).
The above information is a part of company’s filings submitted to BSE.
